title: Therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis.
abstract: The purpose of this study was to evaluate the therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis. Study subjects were classified into two groups according to their pharmacotherapy: the pregabalin group, treated with nonsteroidal anti-inflammatory drug and pregabalin combination therapy, and the control group, treated with nonsteroidal anti-inflammatory drug monotherapy. The two groups were compared in terms of the duration of pain after the onset of leg symptoms and the type of neurogenic intermittent claudication, whether radicular-, caudal-, or mixed-type. Numerical rating scale and Roland-Morris Disability Questionnaire scores were evaluated before and 3 months after treatment. After 3 months of treatment, there were significant differences in the numerical rating scale for radicular- and mixed-types, but not for caudal-type, between the two groups in the subjects with leg symptoms for greater than 3 months. There were significant differences between the two groups in Roland-Morris Disability Questionnaire scores for mixed-type, but not for radicular- and caudal-types, in the subjects with leg symptoms for less than 3 months and for radicular- and mixed-types, but not for caudal-type, in the subjects with leg symptoms for greater than 3 months. Nonsteroidal anti-inflammatory drug and pregabalin combination therapy may be more effective than nonsteroidal anti-inflammatory drug monotherapy for the relief of leg symptoms due to lumbar spinal stenosis, preventing aggravation of subjective symptoms and improving quality of life for patients with radicular- and mixed-types in subjects with leg symptoms for greater than 3 months, although it may be necessary to consider alternative therapy for patients with caudal-type.
authors.affiliation: Department of Orthopaedic Surgery, Southern Tohoku General Hospital.
authors.forename: Naoto
authors.initials: N
authors.lastname: Takahashi
authors.forename: Itaru
authors.initials: I
authors.lastname: Arai
authors.forename: Satoru
authors.initials: S
authors.lastname: Kayama
authors.forename: Kenji
authors.initials: K
authors.lastname: Ichiji
authors.forename: Hironari
authors.initials: H
authors.lastname: Fukuda
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kaga
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Konno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy; D000069583:Pregabalin; D013130:Spinal Stenosis / Q000188:drug therapy* / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid